Cenobamate Monotherapy

The goal of this study is to see how effective cenobamate is as a standalone treatment for adult subjects who have recently been diagnosed with or have experienced a recurring partial-onset seizure. Cenobamate as a standalone treatment is approved by the U.S. Food and Drug Administration (FDA) for adult subjects who have recently been diagnosed with or have experienced a recurring partial-onset seizure; however, there is limited clinical data assessing its use as monotherapy in adults with partial-onset seizures. This study will explore the effectiveness of doses of 100 mg/day and 200 mg/day in this specific population.

Clinicaltrials.gov website:

Study Details | Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy | ClinicalTrials.gov

Sponsor Website:

Cenobamate Monotherapy Study | SK Life Science